Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AT-hook containing transcription factor 1 (AHCTF1, frequently referred to as ELYS) is a multifunctional protein required for assembly of the nuclear pore complex (NPC) during post-mitotic nuclear envelope reformation[1][3]. It enables DNA binding via an AT-hook motif, which allows direct interaction with nucleosomes—this is essential for recruiting and organizing NPC components on chromatin. Beyond its structural roles at the nuclear envelope, AHCTF1 regulates gene expression and is implicated in the efficient nucleocytoplasmic export of transcripts, notably promoting oncogenic MYC expression in some cancer types by serving as a nuclear tether for active gene alleles[1]. AHCTF1 also contributes to genome stability in certain stem and progenitor cell types, and its loss can invoke DNA damage responses even without apparent defects in NPC assembly. Pathologically, AHCTF1 is linked to tumor cell growth via super-enhancer-mediated MYC activation in cancer and congenital contracture syndromes. It is predominantly classified as a transcription factor with nucleoporin and chromatin-binding functions[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AT-hook containing transcription factor 1 (AHCTF1).